Navigation Links
Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal

nk" href= "http://www.expertopin.com/doi/abs/10.1517/13543784.16.7.935">http://www.expertopin.com/doi/abs/10.1517/13543784.16.7.935

About AV411

AV411 is a first-in-class orally bioavailable small molecule, a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. While considered a New Chemical Entity (NCE) in the U.S. and Europe, the drug was first approved in Japan over 15 years ago. The drug has been prescribed to over a million patients and has a good post-marketing safety profile in nearly 15,000 patients dosed at the prescribed doses. Additional information on AV411 can be found on Avigen's website at http://www.avigen.com.

As part of its program investigating glial attenuation as a novel approach to the treatment of neuropathic pain, Avigen discovered that AV411 was efficacious in standard animal models of this condition. While ibudilast was initially developed as a non-selective phosphodiesterase (PDE) inhibitor for the treatment of bronchial asthma, its efficacy in the treatment of neuropathic pain is not dependent on this activity. Based on its research, Avigen has filed for patents protecting this use of AV411 in multiple clinical indications, as well as for patents on AV411 analogs which the company believes have the potential to be effective second generation molecules.

About Neuropathic Pain

Neuropathic pain is one of the most challenging medical conditions to treat. It is an extremely complex pain state that is most often preceded by tissue injury, although the pain state can continue after the initial injury has healed. Nerve fibers may be damaged, dysfunctional or injured, and this in turn sends incorrect signals to other pain centers. It can be an excruciating burning sensation stimulated by a touch that would not normally be perceived as painful, or it can present
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
(Date:12/1/2008)...d today announced the initiation of a Phase 1/2 cl... JAK2 inhibitor, in leading medical centers in Aus...ibrosis (CIMF). , , The trial is designed ...in patients with CIMF and is expected to enrol up ...l assess the safety profile and evaluate the pharm...
(Date:12/1/2008)...NB-0040 at Children,s Hospital, Health Sciences Ce...wswire/ -- Enobia Pharma, an emerging Canadian bio...ics for serious bone disorders, today announced th...m for hypophosphatasia was dosed. Enobia is invest...0040 for the treatment of this rare and often crip...
(Date:12/1/2008)... , ROCHESTER, Minn., Dec. 1 /PRNewswire-USNew...se of the drug therapy etanercept ineffective in t... of the liver caused by excessive consumption of a...the December issue of Gastroenterology ( http://... Additional audio and video resources, including e...
(Date:12/1/2008)...-FirstCall/ -- Following a,Request for Proposal i...sed,third generation smallpox vaccine, Public Wo...the Canadian Department of National Defence, has a...very of IMVAMUNE(R). , The Canadian authori...ntry,s bio-preparedness programme. , The co...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 1Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 2Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 4Human Genome Sciences to Sponsor Conference Call 2319 1Human Genome Sciences to Sponsor Conference Call 2319 2Tufts researchers update their food guide pyramid for older adults 8590 1Tufts researchers update their food guide pyramid for older adults 8590 2Tufts researchers update their food guide pyramid for older adults 8590 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 1Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 2Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 4
...URG, Germany, May 10th, 2007 - Antisense,Pharma, a...argeted,therapies for malignant tumors, today anno...12009 in high-grade glioma will be,presented at th...linical Oncology (ASCO), which will be held in Chi...he open-label, randomized dose-finding Phase,IIb-t...
...praisal Committee concludes that alteplase is clin... 14 May 2007 – A new clinical appraisal,publ...nical,Excellence (NICE) in the UK has recommended ... with acute ischaemic stroke, based on,its clinica...tive,care alone.1 Alteplase is marketed as Actilys...
Other Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:12/2/2008)...SANTA BARBARA, Calif., Dec. 2 Bio...g products and services, and Alere(R) , who provi..., productivity improvement and complex care manage...trophic conditions to health plans, employers, and... BioIQ,s home-test kits and online reporting tools...
(Date:12/2/2008)...LONDON, Dec. 2 Services form an in...turers, (OEMs,) revenues. It has therefore become,...edical imaging services,market to remain competit...tract penetration rates. , (Logo: http://... New analysis from Frost & Sullivan ( htt...
(Date:12/2/2008)... SPEAK to collect and dis... Bellevue, Wash. (PRWEB) Dece...nnounced the launch of a new initiative to focus p... awareness . The official kick-off of SPEAK will o...Pharmacists (ASHP) 2008 Midyear Clinical Meeting, ...
(Date:12/2/2008)... Xena Health and Solution...l Claims Service "Claims in a Cloud" as ...sgow and London (PRWEB) December 2, 2008 -- Making...s to the launch of the first phase of a "Cl... solution from Corporate Modelling partners Xena ...
Breaking Medicine News(10 mins):Health News:BioIQ and Alere to Provide At-Home Biometric Screening Tests to Employees 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 3Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2Health News:Corporate Modelling Partners Start Selling BPM in Cloud Service 2
...holesterol can do to people. High-fat diets cause ...re looking at food labels // to know what they con... easier for consumers to avoid trans fats, which p...ked to an increased risk of heart disease, among o...
...e a greater risk of developing Alzheimer’s, the de...stralian researchers // has claimed. The researc...delphia and the Edith Cowan University in Western ...e 'almost certainly' increases risk from Alzheimer...
...y among the people of Queensland when it comes to ...okesman for Queensland Institute of Medical Resear...drive against skin cancer is not having the desire...MR did not elicit the expected number of responses...
...nd are seeking legal protection in the event of a ...n they would be compelled to work // under adverse...ety (OSH) regulations in force in the country are ... sued as per the law. This is very much likely w...
Other Medicine News:Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3Health News:Obesity could lead to Alzheimer's 2
...iciency and quality to routine urine microscopic a...luorescent flow cytometry with fully automated uri...processing are easily accommodated by the rack-bas... high volume laboratories. Fluorescent flow cytom...
... is a single-use, disposable needle loading device... a Bard BrachyStar needle for interstitial seed im...on safety shield, inner compartment that holds see...lded fitting that connects the cartridge to the ne...
...System uses technology developed by Mortara, the c... digital Holter recorder in 1994. This true 12-lea...r study provides superior ST segment analysis. ,...l recorder allows a full 24-hour 12-lead study to ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems
Medicine Products: